Show simple item record

dc.contributor.authorLutzky, Viviana
dc.contributor.authorDavis, Joanne
dc.contributor.authorCrooks, Pauline
dc.contributor.authorCorban, Monika
dc.contributor.authorSmith, Mark
dc.contributor.authorElliott, Michael
dc.contributor.authorMorrison, Leanne
dc.contributor.authorCross, Simone
dc.contributor.authorTscharke, David
dc.contributor.authorPanizza, Benedict
dc.contributor.authorComan, William
dc.contributor.authorBharadwaj, Mandvi
dc.contributor.authorMoss, Denis
dc.date.accessioned2017-05-03T14:18:42Z
dc.date.available2017-05-03T14:18:42Z
dc.date.issued2009
dc.date.modified2010-07-14T07:43:19Z
dc.identifier.issn08189641
dc.identifier.doi10.1038/icb.2009.25
dc.identifier.urihttp://hdl.handle.net/10072/29251
dc.description.abstractNasopharyngeal carcinoma (NPC) is Epstein-Barr virus (EBV) positive in all undifferentiated cases, expressing the latency II phenotype of latent membrane proteins (LMPs) 1 and 2, in addition to EBV nuclear antigen (EBNA) 1. Several studies have attempted to treat NPC with EBV-specific cytotoxic T lymphocyte (CTL) with a partial response. To improve this therapy, there is a need to expand CTL targeted to the latency II antigens of EBV, rather than the immunodominant EBV nuclear antigens 3-6 peptides typically expanded by lymphoblastoid cells. In order to maximize the expansion of LMP-specific CTL in vitro for use in adoptive immunotherapy of nasopharyngeal carcinoma patients, we used lymphoblastoid cell lines coated with synthetic peptides corresponding to CTL determinants from the LMP proteins. We investigated several issues pertaining to the expansion of an immunologically weak CTL response, including peptide and interleukin-2 concentration, and screening assays for selecting the optimal peptide for use in expansion of LMP-specific CTL. Although screening of ex vivo peripheral blood mononuclear cells did not prove to be useful in the selection of an LMP peptide for use in CTL cultures, the peptide and interleukin-2 concentrations were critical for the maximum expansion of CTL. Therefore, it is imperative that stimulation protocols are optimized for the expansion of LMP-specific CTL.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherNature Publishing Group
dc.publisher.placeUnited Kingdom
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom481
dc.relation.ispartofpageto488
dc.relation.ispartofissue6
dc.relation.ispartofjournalImmunology and Cell Biology
dc.relation.ispartofvolume87
dc.rights.retentionY
dc.subject.fieldofresearchMedical and Health Sciences not elsewhere classified
dc.subject.fieldofresearchBiochemistry and Cell Biology
dc.subject.fieldofresearchImmunology
dc.subject.fieldofresearchcode119999
dc.subject.fieldofresearchcode0601
dc.subject.fieldofresearchcode1107
dc.titleOptimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.date.issued2009
gro.hasfulltextNo Full Text
gro.griffith.authorComan, William B.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record